Emily Gertsch1, Sheila Loharuka2, Kristine Wolter-Warmerdam3, Suhong Tong4, Allison Kempe5, Sita Kedia6. 1. Section of Child Neurology, Children's Hospital Colorado, Aurora, Colorado. 2. Chicago College of Osteopathic Medicine, Droners Grove, Illinois. 3. Neuroscience Institute, Children's Hospital Colorado, Aurora, Colorado. 4. Colorado Biostatistics Consortium, University of Colorado School of Public Health, Aurora, Colorado. 5. Section of General Academic Pediatrics, Aurora, Colorado; The Children's Outcomes Research Program, Children's Hospital Colorado, Aurora, Colorado. 6. Section of Child Neurology, Children's Hospital Colorado, Aurora, Colorado; Neuroscience Institute, Children's Hospital Colorado, Aurora, Colorado; Section of General Academic Pediatrics, Aurora, Colorado; The Children's Outcomes Research Program, Children's Hospital Colorado, Aurora, Colorado.
Abstract
BACKGROUND: Acute i.v. treatment for pediatric headache varies widely. OBJECTIVES: Our aim was to describe our experience with i.v. magnesium for acute treatment of pediatric headache. METHODS: We reviewed the electronic medical records of all patients ages 5 to 18 years old treated with a standard dose of i.v. magnesium for headache at our institution from January 2008 to July 2010. Charts were assessed for headache diagnosis, prior medications given, side effects, tolerability, and response to treatment. Individuals were excluded if they had an underlying unstable medical condition or a secondary etiology for headache. Only first encounters were included if the patient had multiple encounters. RESULTS: There were 34 episodes of children who received i.v. magnesium in the emergency department (ED) or hospital. Of these, 14 were excluded because the patients had complex medical conditions (n = 6), they were repeat encounters (n = 7), or known secondary etiology for the headache (n = 1). Of the 20 included charts (range 13-18 years old), 5 had migraine, 4 had tension-type headache, and 11 had status migrainosus. Thirteen were treated in the ED and seven as an inpatient with a standard i.v. dose of magnesium. Ten of thirteen adolescents receiving i.v. magnesium in the ED were admitted for further headache treatment but not for side effects, and three were discharged home. Side effects of treatment included pain (1 of 20), redness (1 of 20), burning (1 of 20), and decreased respiratory rate without change in oxygenation (1 of 20). CONCLUSIONS: In our case series, adolescents given i.v. magnesium as an abortive therapy for headache experienced minimal side effects and further studies should evaluate for effectiveness.
BACKGROUND: Acute i.v. treatment for pediatricheadache varies widely. OBJECTIVES: Our aim was to describe our experience with i.v. magnesium for acute treatment of pediatricheadache. METHODS: We reviewed the electronic medical records of all patients ages 5 to 18 years old treated with a standard dose of i.v. magnesium for headache at our institution from January 2008 to July 2010. Charts were assessed for headache diagnosis, prior medications given, side effects, tolerability, and response to treatment. Individuals were excluded if they had an underlying unstable medical condition or a secondary etiology for headache. Only first encounters were included if the patient had multiple encounters. RESULTS: There were 34 episodes of children who received i.v. magnesium in the emergency department (ED) or hospital. Of these, 14 were excluded because the patients had complex medical conditions (n = 6), they were repeat encounters (n = 7), or known secondary etiology for the headache (n = 1). Of the 20 included charts (range 13-18 years old), 5 had migraine, 4 had tension-type headache, and 11 had status migrainosus. Thirteen were treated in the ED and seven as an inpatient with a standard i.v. dose of magnesium. Ten of thirteen adolescents receiving i.v. magnesium in the ED were admitted for further headache treatment but not for side effects, and three were discharged home. Side effects of treatment included pain (1 of 20), redness (1 of 20), burning (1 of 20), and decreased respiratory rate without change in oxygenation (1 of 20). CONCLUSIONS: In our case series, adolescents given i.v. magnesium as an abortive therapy for headache experienced minimal side effects and further studies should evaluate for effectiveness.
Authors: Ivan Urits; Jai Won Jung; Ariunzaya Amgalan; Luc Fortier; Anthony Anya; Brendan Wesp; Vwaire Orhurhu; Elyse M Cornett; Alan D Kaye; Farnad Imani; Giustino Varrassi; Henry Liu; Omar Viswanath Journal: Anesth Pain Med Date: 2021-02-06
Authors: Adam A Vukovic; Selena Hariharan; Michelle C Caruso; Sara M Zellner; Marielle Kabbouche; Stephen C Porter; Eileen Murtagh-Kurowski Journal: Pediatr Qual Saf Date: 2021-07-28